TB-500
Fragment of thymosin beta-4 — cell migration
Experimental material. Read before using anything from here.
Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.
Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.
Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.
Summary
Synthetic 7-amino-acid fragment of thymosin beta-4, a larger peptide present throughout the body. The sequence is Ac-LKKTETQ, corresponding to amino acids 17–23 of Tβ4. The 'Ac' prefix indicates acetylation at one end. Interest lies in cell migration and systemic repair, rather than local repair like BPC-157.
Quick reference
- Route
- Subcutaneous in most protocols. Some animal studies use IM or intraperitoneal.
- Concentration
- 10 mg vial + 2 mL of bacteriostatic water = 5 mg/mL. On the U-100, 10 units = 0.10 mL ≈ 500 mcg.
- Schedule
- Loading phase (2×/week) followed by maintenance (1×/week).
- Cycle
- 4–12 weeks. Long maintenance phases are discussed less consistently.
Dosing patterns
| Phase | Weekly amount | Frequency | Duration |
|---|---|---|---|
| Loading | ~4-5 mg/week | 2x per week | Weeks 1-6 |
| Maintenance | ~2-2.5 mg/week | 1×/week | Weeks 7-12 |
| Off period | 0 mg | None | 4–8 weeks |
Dosing patterns
| Phase | Per-dose amount | Frequency | Duration |
|---|---|---|---|
| Front-loading | ~2-2.5 mg | Every 2-3 days | Weeks 1-2 |
| Taper | ~2-2.5 mg | 1×/week | Weeks 3-8 |
Cycle Guidelines
| Approach | Duration | Off period | Best for |
|---|---|---|---|
| Short cycle | 4-6 weeks | 4 weeks | Single research-question focus |
| Standard cycle | 8–12 weeks | 4–8 weeks | Most community-referenced plans |
| Maintenance after load | 1×/week, 6–12 weeks | Variable | Continuation after a 4-6 week loading phase |
TB-500 Reconstitution Guide
| Vial size | BAC water added | Concentration | 10 unit draw | 100 unit draw |
|---|---|---|---|---|
| 10 mg | 2.0 mL | 5.0 mg/mL | 0.10 mL = 500 mcg | 0.50 mL = 2.5 mg |
| 10 mg | 3.0 mL | 3.33 mg/mL | 0.10 mL = 333 mcg | 0.75 mL = 2.5 mg |
TB-500 vs BPC-157
| Reference | TB-500 | Thymosin beta-4 (full) | BPC-157 |
|---|---|---|---|
| Length | 7 amino acids | 43 amino acids | 15 amino acids |
| Source | Synthetic fragment | Endogenous peptide | Synthetic, derived from gastric juice |
| Primary mechanism reference | Actin binding (fragment) | Actin sequestration; broader signaling | Growth factor / angiogenic / cytoprotective signaling |
| Strongest human evidence | None for the fragment specifically | Phase 2 wound, Phase 3 ocular (topical) | Small open-label and case series for joint pain |
| FDA status | Not approved; PCAC review on July 23, 2026 | Not approved; investigational in topical/ophthalmic formulations | Not approved; PCAC review on July 23, 2026 |
| WADA status | Prohibited (S0) | Prohibited (S0) | Prohibited (S0) |
Storage and handling
The rules below apply to practically every lyophilized peptide in this reference. Where a compound has its own requirement, it appears in the table in the previous section.
- Lyophilized powder, sealed: refrigerator, between 2 and 8 °C, protected from light. Many tolerate room temperature for short transport periods, but that is tolerance, not a recommendation.
- After reconstitution: always refrigerated, between 2 and 8 °C. The stability window drops to days or a few weeks, depending on the compound.
- Never freeze after reconstituting. The freeze–thaw cycle degrades the peptide.
- Do not shake. Swirl the vial slowly. Shaking breaks the peptide chain.
- Bacteriostatic water down the wall of the vial, in a slow stream, not squirted directly onto the powder.
- Cloudy solution, with particles or a color change: discard. There is no recovery.
Lab tests and monitoring
This list is the one that appears recurrently in the source, with small variations by compound. It serves as a starting point for a conversation with a professional — not as a substitute for that conversation.
- Before starting: complete blood count, comprehensive metabolic panel, lipid panel, fasting glucose and HbA1c, TSH and free T4, blood pressure and resting heart rate.
- Depending on the compound: IGF-1 (GH axis), lipase and amylase (VIP and the incretin agonists), serum copper and ceruloplasmin (GHK-Cu and blends containing it), CRP.
- Reassessment: most protocols review between week 4 and week 8, and then every 8–12 weeks.
- Do not wait for the routine lab test in the face of abdominal pain, visual changes, a change in a mole, shortness of breath, asymmetric swelling or any new and persistent symptom. That is a reason to seek care, not a spreadsheet item.
Evidence limits
Data source: peptidedosingprotocols.com, accessed on September 3, 2026. Translation and organization in Portuguese are original work. No primary source (PubMed, trial registry, package insert) was checked in building this page — the check was against the secondary source, and that alone.